CRO Selection for Small Pharma and Biotech (2011)


Some Contract Research Organizations (CROs) possess measurable differentiating characteristics that should play an important role in the selection process for clinical studies. This is especially important for small pharma and biotech sponsors that have needs that may be meaningfully different than large pharma.

The challenge faced by the industry is that when making provider selections, development teams have only their own professional histories to reference. Unless a company, or the people it employs, has direct experience with a service provider, there is no independent assessment available to make a confident and informed purchase decision.

This report is designed to provide biopharmaceutical companies and service providers a view into how the consumers of these services grade their performance and how service providers are perceived by the broader market.


  • Performance of 19 CROs, as measured by respondents from small and mid-sized sponsors
  • How small and mid-sized sponsors make their clinical outsourcing decisions, including which service attributes drive selection
  • Attitudes, beliefs, and intentions for future outsourcing
  • For buyers of clinical research service, this report offers insight into CRO service quality specifically for small and mid-sized sponsors. This empowers you to make smarter clinical outsourcing decisions by providing evaluation and selection tools.
  • For clinical service providers, this critical report offers insight into your service quality for small and mid-sized sponsors, your competitors’ quality, buyers’ needs, CRO selection criteria, paths to differentiation, and clinical outsourcing trends and forecasts.
  1. CRO Usage: We kickoff the report by outlining the CRO usage patterns among small pharma and biotech sponsors
  2. CRO Selection: CRO Usage leads us into a discussion of how small pharma and biotech companies select their service providers. Here, small pharma and biotech sponsors tell ISR how they consider more than 2 dozen different high-value CRO attributes. Importantly, we do this by phase, operating with the hypothesis that selection of CROs for Phase I services is different than for Phase II/III and Phase IV.
  3. Service Quality, Satisfaction, and Loyalty: CRO Selection gives way to an evaluation of service quality. Sponsors rate their service providers across 20 different dimensions. Afterward, ISR collapses service providers into their respective size segments and analyzes their performance as distinct groups.
  4. Appendix of Charts and Graphs: The final section provides answers to all questions asked and gives each individual service provider’s service quality performance profile.

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at

Additional information


, ,


There are no reviews yet.

Be the first to review “CRO Selection for Small Pharma and Biotech (2011)”